Literature DB >> 25382267

The Role of Rac1 on Carbachol-induced Contractile Activity in Detrusor Smooth Muscle from Streptozotocin-induced Diabetic Rats.

Atiye Sinem Evcim1, Serap Cilaker Micili, Meral Karaman, Guven Erbil, Ensari Guneli, Sedef Gidener, Mukaddes Gumustekin.   

Abstract

This study was designed to determine the role of the small GTPase Rac1 on carbachol-induced contractile activity in detrusor smooth muscle using small inhibitor NSC 23766 in diabetic rats. Rac1 expression in bladder tissue was also evaluated. In the streptozotocin (STZ)-induced diabetic rat model, three study groups were composed of control, diabetic and insulin-treated diabetic subjects. The detrusor muscle strips were suspended in organ baths at the end of 8-12 weeks after STZ injection. Carbachol (CCh) (10(-9) -10(-4) M) concentration-response curves were obtained both in the absence and in the presence of Rac1 inhibitor NSC 23766 (0.1, 1 and 10 μM). Diabetes-related histopathological changes and Rac1 expressions were assessed by haematoxylin and eosin staining and immunohistochemical staining, respectively. CCh caused dose-dependent contractile responses in all the study groups. Rac1 inhibitor NSC 23766 inhibited CCh-induced contractile responses in all groups, but this inhibition seen in both diabetes groups was greater than in the control group. Histological examination revealed an increased bladder wall thickness both in the diabetes and in the insulin-treated diabetes groups compared to the control group. In immunohistochemical staining, expression of Rac1 was observed to be increased in all layers of bladder in both diabetic groups compared to the control group. In the diabetic bladders, increased expression of Rac1 and considerable inhibition of CCh-induced responses in the presence of NSC 23766 compared to those of the control group may indicate a specific role of Rac1 in diabetes-related bladder dysfunction, especially associated with cholinergic mediated detrusor overactivity.
© 2014 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25382267     DOI: 10.1111/bcpt.12346

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  5 in total

1.  Daidzein attenuates urinary bladder dysfunction in streptozotocin-induced diabetes in rats by NOX-4 and RAC-1 inhibition.

Authors:  Ankit P Laddha; Yogesh A Kulkarni
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-05-11       Impact factor: 3.195

Review 2.  Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder.

Authors:  Vincent Sauzeau; Julien Beignet; Christian Bailly
Journal:  Biomedicines       Date:  2022-06-08

Review 3.  Established and emerging treatments for diabetes-associated lower urinary tract dysfunction.

Authors:  Betül R Erdogan; Guiming Liu; Ebru Arioglu-Inan; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-05-12       Impact factor: 3.195

4.  miR-363 Alleviates Detrusor Fibrosis via the TGF-β1/Smad Signaling Pathway by Targeting Col1a2 in Rat Models of STZ-Induced T2DM.

Authors:  Xue-Feng Li; Shu-Hua Zhang; Gui-Feng Liu; Shao-Nan Yu
Journal:  Mol Ther Nucleic Acids       Date:  2020-07-10       Impact factor: 10.183

Review 5.  Regulation of smooth muscle contraction by monomeric non-RhoA GTPases.

Authors:  Bingsheng Li; Ruixiao Wang; Yiming Wang; Christian G Stief; Martin Hennenberg
Journal:  Br J Pharmacol       Date:  2020-07-19       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.